India markets closed
  • BSE SENSEX

    52,950.63
    +363.79 (+0.69%)
     
  • Nifty 50

    15,885.15
    +122.10 (+0.77%)
     
  • Dow

    35,059.10
    +123.63 (+0.35%)
     
  • Nasdaq

    14,765.48
    +92.80 (+0.63%)
     
  • BTC-INR

    2,954,318.50
    -129,137.00 (-4.19%)
     
  • CMC Crypto 200

    971.92
    +11.02 (+1.15%)
     
  • Hang Seng

    26,235.80
    +274.77 (+1.06%)
     
  • Nikkei

    27,781.02
    +497.43 (+1.82%)
     
  • EUR/INR

    88.3762
    +0.1034 (+0.12%)
     
  • GBP/INR

    103.3480
    -0.0135 (-0.01%)
     
  • AED/INR

    20.1990
    +0.0050 (+0.02%)
     
  • INR/JPY

    1.4661
    -0.0060 (-0.41%)
     
  • SGD/INR

    55.0010
    +0.0980 (+0.18%)
     

Scientists develop 'universal' vaccine to tackle COVID-19, variants, other coronaviruses

·2-min read


Scientists develop
Scientists develop

24 Jun 2021: Scientists develop 'universal' vaccine to tackle COVID-19, variants, other coronaviruses

Researchers have developed a "universal" vaccine for coronaviruses, which has been found to protect mice against COVID-19, along with other group 2B coronaviruses. The study—led by scientists at the University of North Carolina (UNC) Gillings School of Global Public Health—found that the vaccine protected the mice against a dangerous COVID-19 variant as well. The study takes precedence as several COVID-19 variants are now emerging.

Details: Researchers used mRNA technology, used in Pfizer vaccine

The study—published in the Science journal—was conducted by a team of scientists from UNC-Chapel Hill, Duke University School of Medicine, and the University of Pennsylvania Perelman School of Medicine. For the "universal" vaccine, the researchers utilized mRNA from multiple coronaviruses and welded them together, said a statement from the UNC. Pfizer and Moderna vaccines use this technology, however, with mRNA from only one virus.

Results: Vaccine generated antibodies against multiple spike proteins

The hybrid mRNA vaccine managed to generate neutralizing antibodies in mice against multiple spike proteins (used by coronaviruses to latch onto host cells). One of these spike proteins is associated with the B.1.351 variant of SARS-CoV-2, first detected in South Africa. According to the study, the hybrid vaccine prevented both infection and lung damage in mice infected with SARS-CoV-2 and related coronaviruses.

Quote: 'Vaccine has potential to prevent SARS-CoV-3'

Study author Dr. Ralph Baric, said, "The vaccine has the potential to prevent outbreaks when used as a new variant is detected." "Our findings look bright for the future because they suggest we can design more universal coronavirus vaccines to proactively guard against viruses we know are at risk for emerging in humans," said co-author Dr. David Martinez, adding that we could prevent SARS-CoV-3.

Viruses: Focus on sarbecoviruses to prevent future pandemics

The researchers focused on SARS-CoV-2 and other 2B coronaviruses, belonging to the subgenus sarbecovirus. Two sarbecoviruses, SARS-CoV-1 (2002-04 SARS epidemic) and SARS-CoV-2 (ongoing COVID-19 pandemic), have had devastating impacts in the past two decades. Focusing on the group of coronaviruses, which have the potential to jump from animals to humans, may help prevent a future coronavirus pandemic.

The news article, Scientists develop 'universal' vaccine to tackle COVID-19, variants, other coronaviruses appeared first on NewsBytes.

Also see: Will vaccines work against Delta Plus variant? ICMR begins study
Delta Plus: All about the new COVID-19 variant
Delta Plus: How dangerous is the new variant of coronavirus?
Read more on Science by NewsBytes.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting